Precision BioSciences Receives $7.5M Milestone Payment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 02 2026
0mins
Should l Buy DTIL?
Precision BioSciences (DTIL) announced the achievement of a clinical milestone under its license agreement with TG Therapeutics (TGTX). The milestone payment for azercabtagene zapreleucel was triggered by progress of a Phase 1 clinical trial of azer-cel in progressive forms of multiple sclerosis. As a result of this milestone event, Precision will receive $7.5M in proceeds, inclusive of $5.25M cash and $2.25M for the purchase of 201,504 shares of Precision common stock by TG Therapeutics at $11.17 per share, pursuant to the terms of the companies' license agreement. Existing cash and cash equivalents, inclusive of the azer-cel milestone proceeds, continued fiscal and operating discipline, and availability of the ATM facility, are expected to provide sufficient cash runway through 2028. In January 2024, Precision BioSciences announced a licensing deal, granting TG Therapeutics exclusive worldwide rights to develop and commercialize azer-cel in autoimmune diseases and other non-oncology indications. Under the agreement, Precision received upfront and potential near-term economics and remains eligible for additional development, regulatory, and commercial milestone payments, as well as royalties on net sales. Precision is eligible to receive up to $288M in additional milestone payments as well as high-single-digit to low-double-digit royalties on net sales.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DTIL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DTIL
Wall Street analysts forecast DTIL stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.610
Low
30.00
Averages
45.00
High
60.00
Current: 4.610
Low
30.00
Averages
45.00
High
60.00
About DTIL
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Grants Fast Track Designation to PBGENE-DMD for DMD Treatment
- Fast Track Designation: Precision BioSciences announced that its gene editing therapy PBGENE-DMD has received Fast Track designation from the FDA, aimed at expediting the development of treatments for Duchenne muscular dystrophy (DMD), highlighting the significant unmet medical need in this condition.
- Clinical Study Plans: The company plans to host a virtual webinar on March 17, 2026, to discuss the clinical utility of PBGENE-DMD and the upcoming Phase 1/2 FUNCTION-DMD clinical study, which is expected to provide new treatment options for DMD patients.
- Therapeutic Innovation: PBGENE-DMD utilizes a unique gene excision approach targeting mutations in exons 45-55 affecting 60% of DMD patients, designed to permanently edit the dystrophin gene through a single AAV vector encoding two ARCUS proteins, thereby restoring the production of functional muscle protein.
- Preclinical Study Results: In preclinical studies, PBGENE-DMD demonstrated significant functional improvements by restoring near full-length functional dystrophin protein across various muscle types, indicating its potential efficacy and long-term durability in treating DMD.
See More
Precision BioSciences' PBGENE-DMD Receives FDA Fast Track Designation
- Fast Track Designation: Precision BioSciences' investigational therapy PBGENE-DMD has received Fast Track designation from the FDA, aimed at accelerating the development of treatments for Duchenne muscular dystrophy, addressing significant unmet medical needs in this area.
- Regulatory Milestone: CEO Michael Amoroso stated that this designation represents an important regulatory milestone for PBGENE-DMD, highlighting the urgent need for effective treatments for patients suffering from Duchenne muscular dystrophy.
- Clinical Advancement: The Fast Track designation, along with the recent IND clearance, is expected to propel PBGENE-DMD's clinical investigation in boys with Duchenne muscular dystrophy, enhancing its competitive position in the market.
- Market Potential: With FDA support, PBGENE-DMD is poised to achieve positive outcomes in future clinical trials, providing a strong impetus for Precision BioSciences' growth in the rare disease sector.
See More
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD
- Fast Track Designation: Precision BioSciences' PBGENE-DMD has received FDA Fast Track designation, aimed at expediting the development and review of treatments for Duchenne muscular dystrophy (DMD), highlighting the significant unmet medical need in this area.
- Clinical Study Plans: The company plans to host a virtual KOL event on March 17, 2026, to discuss PBGENE-DMD and its upcoming Phase 1/2 FUNCTION-DMD clinical study, which is expected to provide new treatment options for DMD patients.
- Technological Innovation: PBGENE-DMD utilizes a gene excision approach targeting mutations in exons 45-55, potentially offering durable functional muscle improvement for up to 60% of boys with DMD, showcasing its uniqueness and potential in the treatment landscape.
- Preclinical Research Results: In preclinical studies, PBGENE-DMD demonstrated significant functional improvements in a DMD mouse model, restoring function across cardiac, diaphragm, and various skeletal muscles, indicating its feasibility and efficacy for future clinical applications.
See More
FDA Approval Enables Initiation of DMD Clinical Trial
- Clinical Trial Launch: The FDA's 'Study May Proceed' notification allows Precision BioSciences to initiate the FUNCTION-DMD Phase 1/2 clinical trial, aimed at evaluating the safety and efficacy of PBGENE-DMD in patients with Duchenne muscular dystrophy (DMD), marking a significant advancement in the gene editing field.
- Gene Editing Innovation: PBGENE-DMD employs a gene excision approach designed to permanently correct the dystrophin gene in approximately 60% of DMD patients, restoring near full-length functional dystrophin protein, which is expected to significantly improve functional outcomes for patients and offer potential long-term therapeutic effects.
- Investor Event Arrangement: The company plans to host a virtual investor event in March following the Muscular Dystrophy Association meeting to discuss the PBGENE-DMD program and the FUNCTION-DMD clinical study, featuring participation from multiple key opinion leaders, thereby enhancing collaboration with patients and the medical community.
- Future Outlook: The first clinical trial site is expected to be activated in the first half of 2026, with initial data anticipated by the end of 2026; if supportive data is obtained, the company will engage with the FDA to align on the regulatory path forward, advancing treatment options for DMD.
See More
Precision BioSciences Receives FDA Approval for Clinical Trial
- FDA Clinical Trial Approval: Precision BioSciences received a 'Study May Proceed' notification from the FDA, allowing the initiation of the FUNCTION-DMD Phase 1/2 clinical trial to evaluate the safety and efficacy of PBGENE-DMD in patients with Duchenne muscular dystrophy, marking a significant advancement in the gene editing field.
- Gene Editing Innovation: PBGENE-DMD utilizes a gene excision approach targeting mutations in exons 45-55 affecting 60% of DMD patients, aiming to restore near full-length functional dystrophin protein, which is expected to significantly improve muscle function and address existing treatment gaps.
- Clinical Trial Progress: The company plans to activate its first clinical trial site in the U.S. in the first half of 2026, with initial data expected by year-end 2026; if results are supportive, the company will engage with the FDA to discuss the regulatory pathway forward, demonstrating its commitment to accelerating treatment progress.
- Investor Event Arrangement: Precision plans to host a virtual investor event in March following the Muscular Dystrophy Association meeting to discuss the PBGENE-DMD program and the FUNCTION-DMD clinical study, featuring participation from key opinion leaders in the medical and patient advocacy communities, enhancing communication with stakeholders.
See More
Precision BioSciences Advances PBGENE-HBV and PBGENE-DMD Trials, Data Updates Expected in 2026
- Clinical Trial Progress: Precision BioSciences' PBGENE-HBV is currently undergoing the Phase 1/2a ELIMINATE-B trial, which has shown dose-dependent antiviral activity, with data updates expected at medical conferences in 2026, potentially offering a cure for chronic hepatitis B patients.
- Strong Financial Position: As of December 31, 2025, Precision anticipates having approximately $137 million in cash and cash equivalents, which is expected to fund key data milestones for PBGENE-HBV and PBGENE-DMD, ensuring operational stability through 2028.
- New DMD Treatment Approach: The PBGENE-DMD Phase 1/2 FUNCTION-DMD trial is expected to receive IND clearance in Q1 2026, aiming to provide durable functional muscle improvement for 60% of DMD patients, with initial data anticipated by the end of 2026.
- Collaborative Project Advancements: The ECUR-506 project with iECURE has reached key alignment with the FDA, supporting its potential as a curative treatment for neonatal OTC deficiency, with clinical trial data expected to be released in the first half of 2026, further enhancing Precision's market position.
See More
FDA Grants Fast Track Designation to PBGENE-DMD for DMD Treatment
- Fast Track Designation: Precision BioSciences announced that its gene editing therapy PBGENE-DMD has received Fast Track designation from the FDA, aimed at expediting the development of treatments for Duchenne muscular dystrophy (DMD), highlighting the significant unmet medical need in this condition.
- Clinical Study Plans: The company plans to host a virtual webinar on March 17, 2026, to discuss the clinical utility of PBGENE-DMD and the upcoming Phase 1/2 FUNCTION-DMD clinical study, which is expected to provide new treatment options for DMD patients.
- Therapeutic Innovation: PBGENE-DMD utilizes a unique gene excision approach targeting mutations in exons 45-55 affecting 60% of DMD patients, designed to permanently edit the dystrophin gene through a single AAV vector encoding two ARCUS proteins, thereby restoring the production of functional muscle protein.
- Preclinical Study Results: In preclinical studies, PBGENE-DMD demonstrated significant functional improvements by restoring near full-length functional dystrophin protein across various muscle types, indicating its potential efficacy and long-term durability in treating DMD.
See More
Precision BioSciences' PBGENE-DMD Receives FDA Fast Track Designation
- Fast Track Designation: Precision BioSciences' investigational therapy PBGENE-DMD has received Fast Track designation from the FDA, aimed at accelerating the development of treatments for Duchenne muscular dystrophy, addressing significant unmet medical needs in this area.
- Regulatory Milestone: CEO Michael Amoroso stated that this designation represents an important regulatory milestone for PBGENE-DMD, highlighting the urgent need for effective treatments for patients suffering from Duchenne muscular dystrophy.
- Clinical Advancement: The Fast Track designation, along with the recent IND clearance, is expected to propel PBGENE-DMD's clinical investigation in boys with Duchenne muscular dystrophy, enhancing its competitive position in the market.
- Market Potential: With FDA support, PBGENE-DMD is poised to achieve positive outcomes in future clinical trials, providing a strong impetus for Precision BioSciences' growth in the rare disease sector.
See More
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD
- Fast Track Designation: Precision BioSciences' PBGENE-DMD has received FDA Fast Track designation, aimed at expediting the development and review of treatments for Duchenne muscular dystrophy (DMD), highlighting the significant unmet medical need in this area.
- Clinical Study Plans: The company plans to host a virtual KOL event on March 17, 2026, to discuss PBGENE-DMD and its upcoming Phase 1/2 FUNCTION-DMD clinical study, which is expected to provide new treatment options for DMD patients.
- Technological Innovation: PBGENE-DMD utilizes a gene excision approach targeting mutations in exons 45-55, potentially offering durable functional muscle improvement for up to 60% of boys with DMD, showcasing its uniqueness and potential in the treatment landscape.
- Preclinical Research Results: In preclinical studies, PBGENE-DMD demonstrated significant functional improvements in a DMD mouse model, restoring function across cardiac, diaphragm, and various skeletal muscles, indicating its feasibility and efficacy for future clinical applications.
See More
FDA Approval Enables Initiation of DMD Clinical Trial
- Clinical Trial Launch: The FDA's 'Study May Proceed' notification allows Precision BioSciences to initiate the FUNCTION-DMD Phase 1/2 clinical trial, aimed at evaluating the safety and efficacy of PBGENE-DMD in patients with Duchenne muscular dystrophy (DMD), marking a significant advancement in the gene editing field.
- Gene Editing Innovation: PBGENE-DMD employs a gene excision approach designed to permanently correct the dystrophin gene in approximately 60% of DMD patients, restoring near full-length functional dystrophin protein, which is expected to significantly improve functional outcomes for patients and offer potential long-term therapeutic effects.
- Investor Event Arrangement: The company plans to host a virtual investor event in March following the Muscular Dystrophy Association meeting to discuss the PBGENE-DMD program and the FUNCTION-DMD clinical study, featuring participation from multiple key opinion leaders, thereby enhancing collaboration with patients and the medical community.
- Future Outlook: The first clinical trial site is expected to be activated in the first half of 2026, with initial data anticipated by the end of 2026; if supportive data is obtained, the company will engage with the FDA to align on the regulatory path forward, advancing treatment options for DMD.
See More
Precision BioSciences Receives FDA Approval for Clinical Trial
- FDA Clinical Trial Approval: Precision BioSciences received a 'Study May Proceed' notification from the FDA, allowing the initiation of the FUNCTION-DMD Phase 1/2 clinical trial to evaluate the safety and efficacy of PBGENE-DMD in patients with Duchenne muscular dystrophy, marking a significant advancement in the gene editing field.
- Gene Editing Innovation: PBGENE-DMD utilizes a gene excision approach targeting mutations in exons 45-55 affecting 60% of DMD patients, aiming to restore near full-length functional dystrophin protein, which is expected to significantly improve muscle function and address existing treatment gaps.
- Clinical Trial Progress: The company plans to activate its first clinical trial site in the U.S. in the first half of 2026, with initial data expected by year-end 2026; if results are supportive, the company will engage with the FDA to discuss the regulatory pathway forward, demonstrating its commitment to accelerating treatment progress.
- Investor Event Arrangement: Precision plans to host a virtual investor event in March following the Muscular Dystrophy Association meeting to discuss the PBGENE-DMD program and the FUNCTION-DMD clinical study, featuring participation from key opinion leaders in the medical and patient advocacy communities, enhancing communication with stakeholders.
See More
Precision BioSciences Advances PBGENE-HBV and PBGENE-DMD Trials, Data Updates Expected in 2026
- Clinical Trial Progress: Precision BioSciences' PBGENE-HBV is currently undergoing the Phase 1/2a ELIMINATE-B trial, which has shown dose-dependent antiviral activity, with data updates expected at medical conferences in 2026, potentially offering a cure for chronic hepatitis B patients.
- Strong Financial Position: As of December 31, 2025, Precision anticipates having approximately $137 million in cash and cash equivalents, which is expected to fund key data milestones for PBGENE-HBV and PBGENE-DMD, ensuring operational stability through 2028.
- New DMD Treatment Approach: The PBGENE-DMD Phase 1/2 FUNCTION-DMD trial is expected to receive IND clearance in Q1 2026, aiming to provide durable functional muscle improvement for 60% of DMD patients, with initial data anticipated by the end of 2026.
- Collaborative Project Advancements: The ECUR-506 project with iECURE has reached key alignment with the FDA, supporting its potential as a curative treatment for neonatal OTC deficiency, with clinical trial data expected to be released in the first half of 2026, further enhancing Precision's market position.
See More
